Press Releases

Press Releases

  • April 20, 2017
    NLS Pharma Announces Presentations at 6th World Congress on ADHD

    READ PRESS RELEASE

  • April 18, 2017
    NLS Pharma Announces Completion of Phase 2 Study for NLS-1, Its Lead ADHD Compound; New Investors, New Patents

    READ PRESS RELEASE

  • December 3, 2016
    NLS Pharma Named Winner Of A Prestigous 2016 Healthcare & Life Sciences Award

    READ PRESS RELEASE

  • August 29, 2016
    NLS Pharma announces start of its phase 2 trial for Mazindol in adult ADHD patients

    READ PRESS RELEASE

  • July 11, 2016
    Mazindol granted orphan drug designation in the US & Europe for treatment of Narcolepsy

    READ PRESS RELEASE

  • June 16, 2016
    FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD

    READ PRESS RELEASE

  • May 12, 2016
    NLS Pharma Announces IND submission for Controlled-Release Mazindol to Treat Adults with ADHD.

    READ PRESS RELEASE